Evidence map›Paper›PMID 40935611›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Iris Y Zhou, Caiyuan Zhang, Mozhdeh Sojoodi, Nicholas J Rotile, Yu Lan, Stephen C Barrett, Changning Wang, Caralee J Schaefer, Karl Kossen, Scott D Seiwert and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Iris Y ZhouAthinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; iris.zhou@mgh.harvard.edu pcaravan@mgh.harvard.edu.
Caiyuan ZhangAthinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.
Mozhdeh SojoodiDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts; and.
Nicholas J RotileAthinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.
Yu LanAthinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.
Stephen C BarrettDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts; and.
Changning WangAthinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.
Caralee J SchaeferIndalo Therapeutics, St. Charles, Missouri.
Karl KossenIndalo Therapeutics, St. Charles, Missouri.
Scott D SeiwertIndalo Therapeutics, St. Charles, Missouri.
Kenneth K TanabeDivision of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts; and.
Peter CaravanAthinoula A. Martinos Center for Biomedical Imaging, The Institute for Innovation in Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; iris.zhou@mgh.harvard.edu pcaravan@mgh.harvard.edu.

Funding

Molecular MR Imaging of Hepatic FibrogenesisR01DK121789 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Peter D Caravan · 2019 to 2026
$5.0M
Quantitative MRI-PET Imaging of Pulmonary FibrosisK25HL148837 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ZHOU, IRIS YUWEN · 2020 to 2023
$686k
MRI-Compatible PET Insert for Small Bore ScannerS10OD023503 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2017 to 2017
$600k
Inductively Coupled Plasma Mass SpectrometerS10OD032138 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2022 to 2022
$598k
Electronics Upgrade for 11.7 TS10OD025234 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2018 to 2018
$595k
Automation Equipment for Human PET Radiotracer ProductionS10OD028499 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CARAVAN, PETER D · 2021 to 2021
$325k
NHLBI NIH HHS K25 HL148837NIDDK NIH HHS R01 DK121789NIH HHS S10 OD023503NIH HHS S10 OD025234NIH HHS S10 OD028499NIH HHS S10 OD032138
6 · The paper itself

Abstract

Patient outcomes in metabolic dysfunction-associated steatohepatitis (MASH) are associated with the presence and stage of liver fibrosis. Activated hepatic stellate cells are a key mediator of MASH fibrogenesis and show increased expression of integrin α

Indexed as

Fatty LiverIntegrinsOligopeptidesPositron-Emission TomographyAnimalsDisease Models, AnimalFluorine RadioisotopesHumansIntegrin alphaVbeta3Liver CirrhosisMaleMicearginyl-glycyl-aspartic acidFluorine RadioisotopesIntegrin alphaVbeta3IntegrinsOligopeptidesintegrin αvβ3liver fibrosisMASHPET/MRIRGD

Identifiers

PMID40935611
PMCPMC12582189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.